Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
http://img.marketwire.com/rss/mwPBES.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  company  development  mar  march  marketwired mar  marketwired march  marketwired  medical  new  pleased announce  shares 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies



Marketwired - Equipment and Supplies



Last Build Date: Wed, 29 Mar 2017 06:33:37 EDT

Copyright: Copyright: (C) Marketwired
 



Genetic Technologies and IndyCar's Pippa Mann Partner for Second Consecutive Year to Promote BREVAGenplus(R)

Wed, 29 Mar 2017 05:30:00 EDT

MELBOURNE, AUSTRALIA--(Marketwired - Mar 29, 2017) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company focused on cancer risk assessment, announced today an agreement with Dale Coyne Racing driver Ms. Pippa Mann to promote BREVAGenplus®, the Company's first-in-class, clinically validated risk assessment test for sporadic breast cancer. The partnership is reflective of the Company's continuation of its U.S. focused marketing program for BREVAGenplus, with Mann serving for a second consecutive term as the product's ambassador and spokesperson. Mann is one of only nine female athletes to ever compete in the "Indy 500" and the only female driver to start in the race over the past four consecutive years. In addition to her role with Genetic Technologies, Mann is partnering with Susan G. Komen®, the world's largest breast cancer organisation, which funds more breast cancer research than any other non-profit, outside of the U.S. government, while providing screening, education, treatment and psychosocial support programs. In 2016, Mann was honoured as one of Komen's More Than PinkT heroes in support of the organisations Bold Goal - to reduce the current number of breast cancer deaths in the U.S. by half, by 2026. 




Atossa Genetics, Inc. Prices $4,000,000 Public Offering

Wed, 29 Mar 2017 01:50:25 EDT

SEATTLE, WA--(Marketwired - Mar 29, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public offering with anticipated gross proceeds of $4,000,000, before deducting underwriting discounts, commissions and other offering expenses. The offering consists of (i) Class A Units consisting of 664,000 shares of our Common Stock and Warrants to purchase 664,000 shares of Common Stock, and (ii) Class B Units consisting of 3,502 shares of our Series A Convertible Preferred Stock, with a face value of $1,000 and each convertible into 1,333.33 shares of Common Stock, and Warrants exercisable for the number of shares of Common Stock into which the shares of Series A Convertible Preferred Stock are convertible. The Warrants will have an exercise price of $0.9375, will be exercisable upon issuance and will expire five years from the date of issuance. Atossa has granted the underwriters a 45-day option to purchase up to an additional 800,000 shares of Common Stock and/or 800,000 Warrants to cover over-allotments, if any. The offering is expected to close on April 3, 2017, subject to customary closing conditions.




Medtronic, DePuy Synthes Lead Cervical and Lumbar Artificial Disc Market Due to Positive Clinical Results and Emerging Technologies

Tue, 28 Mar 2017 12:27:58 EDT

Overall, the U.S. spinal implants and vertebral compression fracture market is expected to increase and reach nearly $7 billion by 2023




LogixHealth Publishes ED Facility-Focused Intelligence Briefing: 2017 Emergency Department Outpatient Payment System Update

Tue, 28 Mar 2017 12:00:00 EDT

BEDFORD, MA--(Marketwired - Mar 28, 2017) - LogixHealth, a leading provider of internet and software enabled coding, billing, analytics and management services for hospital and physician practices nationwide, provides services for millions of Emergency Department (ED) visits nationwide, and has published its newest facility-focused intelligence briefing: 2017 Emergency Department Outpatient Payment System Update. On November 1, 2016, CMS published the 2017 Outpatient Prospective Payment System (OPPS) final rule in the Federal Register, which finalizes payment rates and policies for outpatient services furnished by hospitals that are paid under the OPPS, and governs services provided on or after January 1, 2017. The rule, and the full 2017 Emergency Department Outpatient Payment System Update can be found on the LogixHealth website.




NSAV Announces Cancellation of 3.0 Billion KBM Worldwide Shares

Tue, 28 Mar 2017 10:22:38 EDT

CRESCO, PA--(Marketwired - Mar 28, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has cancelled 3.0 billion shares of its common stock that had been pledged to KBM Worldwide in a settlement negotiated by the Company's previous management. The Company took this action as these shares were part of an agreement between NSAV and its former management and China Food and Beverage Company (OTC: CHIF). The agreement expired on June 30, 2016 and is now null and void. The Company feels that this action is in the best interest of NSAV and its shareholders.




Cytek Biosciences Poised to Accelerate Flow Cytometry Adoption

Tue, 28 Mar 2017 10:00:00 EDT

Seeks to Enable Widespread Access to Cellular, Molecular Analysis for Rapid Disease Diagnosis, Treatment, and Monitoring




USPack Logistics Strengthens Executive Leadership

Tue, 28 Mar 2017 09:30:52 EDT

Frank Powell promoted to chief operating officer and Dan Byrne tapped as vice president of business development




Marijuana Company of America Completes PCOAB Audit

Tue, 28 Mar 2017 08:30:00 EDT

BONSALL, CA--(Marketwired - Mar 28, 2017) - MARIJUANA COMPANY OF AMERICA ("MCOA" or the "Company") (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that its PCAOB auditors have completed a two year audit of the Company's financial statements for the years ended December 31, 2015 and 2016.




Propanc Receives Patentability Opinion for Method of Treating Cancer Stem Cells

Tue, 28 Mar 2017 08:30:00 EDT

International Search Report concludes majority of claims are novel and inventive




ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team

Tue, 28 Mar 2017 08:05:00 EDT

Company Names New Board Member, Continues to Build Out Operations Team Through Appointment and Promotions




MJTV Begins, "What Is A Beautiful Woman", Branding And Marketing Campaign In Advance Of VOLUPTAS Market Launch

Tue, 28 Mar 2017 08:00:00 EDT

WHIPPANY, NJ--(Marketwired - Mar 28, 2017) - Michael James Enterprises, Inc. (OTCQB: MJTV) launches, "What is a Beautiful Woman" branding and marketing campaign in advance of the VOLUPTAS market launch. After much time and thought and conferring with different experts and groups MJTV has set out to describe through an image as a company-wide focus on "What is a Beautiful Woman". Shelley Rizzo, the graphic designer, collaborated with MJTV Chief Operating Officer, Gina Morreale, on the design and descriptive words of the new logo. They also decided to name her -- "BEAUTY".




Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

Tue, 28 Mar 2017 07:30:00 EDT

VALENCIA, SPAIN--(Marketwired - Mar 28, 2017) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS CardiacT, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited ("MML"), our joint venture based at Sci-Tech, Daresbury (UK), has engaged Future Diagnostics Solutions B.V. ("Future Diagnostics") for assay development services.




Akers Biosciences Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check

Tue, 28 Mar 2017 07:00:00 EDT

THOROFARE, NJ--(Marketwired - Mar 28, 2017) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has received an initial order for the Company's rapid cholesterol self-test from First Check Diagnostics, LLC ("First Check"), the exclusive distributor for this product in the United States, for sale under their popular "First Check" brand.




Pyng Receives Securityholder Approval for Acquisition by Teleflex

Mon, 27 Mar 2017 21:18:50 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 27, 2017) - Pyng Medical Corp. (the "Company" or "Pyng") (TSX VENTURE:PYT) is pleased to announce that the previously announced acquisition of all of the issued and outstanding common shares of Pyng (the "Shares") by Teleflex Medical Canada Inc., a wholly-owned subsidiary of Teleflex Incorporated, by way of plan of arrangement (the "Arrangement"), has been approved by the holders (the "Securityholders") of Pyng's Shares, options, warrants and convertible debentures. At the special meeting of Pyng Securityholders held on March 27, 2017 (the "Meeting"), a special resolution approving the Arrangement was approved by 99.97% of the votes cast by the shareholders of Pyng, voting as a single class, present in person or represented by proxy and entitled to vote at the meeting, approved by 99.98% of votes cast by Securityholders, voting as a single class, present in person or represented by proxy and entitled to vote at the Meeting and approved by 99.96% of the votes cast by shareholders of Pyng present in person or represented by proxy and entitled to vote at the Meeting, excluding votes cast by those persons whose votes must be excluded pursuant to applicable securities law.




CBIS Ramps Up Production and Releases More New Products to Meet the Substantial Requests From Self-Medicating Patients Across the Country as it Highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017

Mon, 27 Mar 2017 15:40:40 EDT

CBIS Sets the Stage to Meet the Increasing Consumer Demand With Even More Medicinal Products for its Nationwide Observational and Clinical Studies




Hearing Industries Association (HIA) Response to the Over-the-Counter Hearing Aid Act of 2017

Mon, 27 Mar 2017 12:00:00 EDT

WASHINGTON, DC--(Marketwired - March 27, 2017) - On March 20, 2017 the Over-the-Counter Hearing Aid Act of 2017 (S.670) was introduced by Senators Elizabeth Warren (D-Mass.), Charles Grassley (R-Iowa), Maggie Hassan (D-N.H.) and Johnny Isakson (R-Ga.). The bill would require the Food and Drug Administration (FDA) to propose a rule to establish an over-the-counter hearing aid (OTC) category for adults with "perceived" mild to moderate hearing loss within three years of passage of the legislation. Representatives Joseph Kennedy III (D-Mass.) and Marsha Blackburn (R-Tenn.) have introduced an Over-the-Counter Hearing Aid bill (H.R. 1652) in the House, which mirrors the Senate bill.




Nutritional High Announces Closing of Oregon Property Acquisition and an Update on Licensing

Mon, 27 Mar 2017 09:57:27 EDT

TORONTO, ONTARIO--(Marketwired - March 27, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(CSE:EAT.CN)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to announce that is has closed an acquisition of a real estate property in The City of La Pine located in Deschutes County, Oregon where the Company intends to extract cannabis oil, and manufacture cannabis infused products. The Company is in the advanced stages of an application process to manufacture cannabis concentrates and edibles with Oregon Liquor Control Commission ("OLCC") in relation to the property.




Ogilvy CommonHealth Worldwide and InTouchMD Announce Partnership

Mon, 27 Mar 2017 09:33:39 EDT

PARSIPPANY, NJ--(Marketwired - Mar 27, 2017) -  Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com) and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced the creation of a formal partnership with InTouchMD (www.intouchmd.com), a leading healthcare marketing and solutions company.




GeoVax Reports on Vaccine Development Progress

Mon, 27 Mar 2017 09:00:00 EDT

Expanding Pipeline for MVA-VLP Vaccine Platform Includes HIV, Zika, Ebola, Malaria, Hepatitis B and Cancer




MK Automotive's Cord-Cutting Service Clikia(TM) Launched

Mon, 27 Mar 2017 09:00:00 EDT

Online Sign-up Open; Device Roll-out begins with Android(R) and Roku(R)




BriaCell Closes CEO Equity Investment

Fri, 24 Mar 2017 18:22:47 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of 5,612,083 units (the "Units") for aggregate gross proceeds to the Company in the amount of $1,346,900 with its President and CEO, Dr. William Williams.




Nutritional High Clarifies Colorado Sales Update

Fri, 24 Mar 2017 17:42:05 EDT

TORONTO, ONTARIO--(Marketwired - March 24, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(CSE:EAT.CN)(OTCQB:SPLIF)(FRANKFURT:2NU) wishes to clarify the Colorado sales update press release made on March 17, 2017.




Kessler Foundation Renews Collaboration with Children's Specialized Hospital

Fri, 24 Mar 2017 14:08:11 EDT

EAST HANOVER, NJ and NEW BRUNSWICK, NJ--(Marketwired - March 24, 2017) - Kessler Foundation, a global leader in rehabilitation research, and Children's Specialized Hospital, the nation's leading provider of inpatient and outpatient care for children facing special health challenges, have renewed their collaboration by signing a three-year agreement, with a funding level of $2.1 million, to continue their research program for children with disabilities.




GeoVax Reports 2016 Year-End Financial Results

Fri, 24 Mar 2017 14:00:00 EDT

ATLANTA, GA--(Marketwired - Mar 24, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2016.




NSAV Announces 2.5 Billion Share Reduction

Fri, 24 Mar 2017 10:31:40 EDT

CRESCO, PA--(Marketwired - Mar 24, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a 2.5 billion reduction of its authorized shares. The Company took this action after lengthy consultation with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place and that NSAV is not planning or even considering a reverse split of its shares.




Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

Fri, 24 Mar 2017 09:10:00 EDT

CITY OF INDUSTRY, CA--(Marketwired - Mar 24, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster1 on the use of antihypertensive for the treatment of cancer by targeting vascular resistance in the tumor will be presented at the Endocrine Society Annual Meeting to be held on April 1-4, 2017, at Orange County Convention Center, Orlando, FL. 




Quadron Completes R&D for Its Automated Odor Elimination System to Eradicate Cannabis Odor

Fri, 24 Mar 2017 08:30:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 24, 2017) - Quadron Capital Corporation (the "Company" or "Quadron") - (CSE:QCC) - is pleased to report the completion of the research and development of its newly designed, proprietary automated Odor Elimination System ("OES") designed specifically for the industrial cannabis industry. The company believes it is the first, and most efficient solution in the market to eliminate residual odors that remain after being filtered by industry standard carbon filtration systems.




The Modernization of eCOA Technology for Clinical Trials, New Webinar Hosted by Xtalks

Fri, 24 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 24, 2017) - During a live session, mobile health solution expert Mike Hughes, Senior Director of eCOA Solutions from YPrime, will provide a timely update on new industry expectations of eCOA technologies. Next generation eCOA platforms have recently evolved to support sophisticated data collection, simplify management from sponsors and sites, and improve patient compliance.




Medigus Announces $7.5 Million Public Offering

Fri, 24 Mar 2017 07:26:11 EDT

OMER, ISRAEL--(Marketwired - Mar 24, 2017) -  Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced the pricing of a best efforts public offering of 979,714 Class A Units at a purchase price per unit of $3.50 and of 1,163,144 Class B Units at an effective purchase price per unit of $3.50. Each Class A unit consists of (i) one American Depositary Share, or ADS, and (ii) one Series A warrant to purchase one ADS, and each Class B unit consists of (i) one pre-funded warrant to purchase one ADS, and (ii) one Series A warrant to purchase one ADS. The offering is expected to result in gross proceeds to the company of approximately $7.5 million.




HCi Viocare Ships its 4th Generation Athletic Smart Insole

Thu, 23 Mar 2017 16:00:00 EDT

GLASGOW, SCOTLAND--(Marketwired - Mar 23, 2017) - HCi Viocare (OTCQB: VICA) is pleased to announce that its wholly owned subsidiary HCi Viocare Technologies, the company behind the revolutionary sensing technology FlexisenseT,  has started shipping its 4th Generation Athletic Smart insoles to the sports shoes manufacturers with whom the company is in discussions.




SNS FiRe Conference Names ElpisEremo a 2017 FiReStarter Company

Thu, 23 Mar 2017 15:13:20 EDT

Global thought leaders converge this October to address some of the world's greatest challenges




Premier Diversified Holdings Inc. Announces Unit Purchase of MyCare MedTech Inc.

Thu, 23 Mar 2017 12:34:12 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 23, 2017) -




Pressure BioSciences, Inc. Significantly Expands Marketing and Sales Capabilities

Thu, 23 Mar 2017 10:27:22 EDT

Company Engages Highly-Regarded Lead Generation Service and Hires the First Two of Four Field Sales Directors, Executing on its Plan to Aggressively Enhance Product Sales Capabilities in 2017




Dr. Brita Hansen joins LogicStream Health as Chief Medical Officer

Thu, 23 Mar 2017 10:00:00 EDT

MINNEAPOLIS, MN--(Marketwired - Mar 23, 2017) - LogicStream Health, Inc. is pleased to announce Dr. Brita Hansen is the company's new Chief Medical Officer. Dr. Hansen comes to LogicStream from Hennepin County Medical Center (HCMC), where she served as Chief Health Information Officer. Prior to her role as CHIO, Dr. Hansen spent many years in quality improvement as the Medical Director of Inpatient Quality and Informatics at HCMC. She is also an assistant professor of medicine at the University of Minnesota School of Medicine.




Dr. Brita Hansen joins LogicStream Health as Chief Medical Officer

Thu, 23 Mar 2017 10:00:00 EDT

MINNEAPOLIS, MN--(Marketwired - Mar 23, 2017) -  LogicStream Health, Inc. is pleased to announce Dr. Brita Hansen is the company's new Chief Medical Officer. Dr. Hansen comes to LogicStream from Hennepin County Medical Center (HCMC), where she served as Chief Health Information Officer. Prior to her role as CHIO, Dr. Hansen spent many years in quality improvement as the Medical Director of Inpatient Quality and Informatics at HCMC. She is also an assistant professor of medicine at the University of Minnesota School of Medicine.




Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology

Thu, 23 Mar 2017 09:29:00 EDT

Company Provides Update on The Development of Its Pipeline of Non-Invasive Electroceuticals Targeting Vascular Diseases and Ischemia/Reperfusion Injuries




Predictive Technology Group, Inc. (PRED) Announces Development Progress of its Non-Invasive DNA Test for Endometriosis in Three Scientific Presentations

Thu, 23 Mar 2017 09:15:00 EDT

Development of the ARTGuide(R) Test for Endometriosis Test Will Rapidly Accelerate Short and Long-Term Company Growth




PCI Synthesis Wins Big at 2017 Life Science Leader Magazine CMO Leadership Awards

Thu, 23 Mar 2017 09:14:00 EDT

Wins "Top Performer" in all 14 categories




Mount Tam Biotechnologies Announces that the Japan Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

Thu, 23 Mar 2017 09:00:00 EDT

NOVATO, CA--(Marketwired - Mar 23, 2017) -  Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors is pleased to announce that the Japanese Patent Office has allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides composition of matter protection for Mount Tam's lead compound in Japan, complementing Mount Tam's strong intellectual property position in the United States.




Atossa Genetics Opens Enrollment in Study of Endoxifen

Thu, 23 Mar 2017 08:41:12 EDT

SEATTLE, WA--(Marketwired - Mar 23, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has opened enrollment of a Phase 1 study of endoxifen, which is an active metabolite of tamoxifen, an FDA approved drug for breast cancer. The objectives of this placebo-controlled, repeat dose study of 48 healthy female volunteers is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability.




Upcoming Webinar Assessing NASH: Discover the Non-Invasive Techniques

Thu, 23 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - On Thursday, April 13, 2017, Xtalks will host a complimentary webinar featuring Dr. Richard Ehman, Professor of Radiology, Blanche R. & Richard J. Erlanger Professor of Medical Research, Mayo Clinic; President and CEO, Resoundant, Inc. and Jonathan Riek, Vice President, Musculoskeletal and Metabolic Imaging, BioTelemetry Research (Cardiocore & VirtualScopics) as the presenters.




Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-time, New Webinar Hosted by Xtalks

Thu, 23 Mar 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - Julie Peacock from Client Services at Comprehend and Linda Sullivan, Co-Founder & President of Metrics Champion Consortium (MCC) will provide an in-depth look at CRO oversight and risk management best practice. Their presentation delves into the gaps in oversight processes, the causes of these gaps and how to successfully address them. The live broadcast takes place on Wednesday, April 12, 2017 at 1pm EDT.




Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

Wed, 22 Mar 2017 20:18:32 EDT

Company to Host an Investor Conference Call on Thursday, March 23, 2017 at 10:00 AM EDT




Pressure BioSciences, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Business Update

Wed, 22 Mar 2017 12:34:20 EDT

55% Growth in Q4 2016 Products & Services Revenue, Including 70% Increase in Sale of Consumable Supplies, Helps Company Achieve 27% Growth in Products & Services Revenue for Fiscal Year 2016

New Product Releases and Expansion of Sales & Marketing Capabilities Expected to Augment Revenue in FY2017

Investor Conference Call Scheduled for Wednesday, March 22, 2017 at 4:30 PM EDT




Science Exchange Named Finalist for Coveted Procurement Leaders World Procurement Awards

Wed, 22 Mar 2017 11:00:00 EDT

Science Exchange on Shortlist for Procurement Service Provider Award; Winners Announced in May




Heartland Dental Founder and Executive Chairman Presents at 2017 ADSO Summit

Wed, 22 Mar 2017 11:00:00 EDT

Dr. Rick Workman discusses the vision and purpose of dental support organizations




Cyrex Laboratories Unveils Array 22 in Canada for Unprecedented Accuracy in Assessing SIBO

Wed, 22 Mar 2017 10:30:00 EDT

New Serum Test Identifies Small Intestine Bacterial Overgrowth (SIBO) to Help Treat Patients Suffering from Irritable Bowels, Malabsorption, Fatigue and More




TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology

Wed, 22 Mar 2017 10:00:00 EDT

TissueGen's ELUTE Fiber Provides Controlled Sustained Delivery of Sensitive Drugs Enabling Nerve Regeneration and Tissue Engineering




Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia

Wed, 22 Mar 2017 09:35:26 EDT

HOUSTON, TX--(Marketwired - March 22, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced its lead candidate, Annamycin (also known as "Liposomal Annamycin"), an anthracycline, has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).




AXIM Signs CRO Deal with Ophthalmology Trials -- SECFilings.com

Wed, 22 Mar 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - Mar 22, 2017) - SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.'s (OTCQB: AXIM) recent engagement of a contract research organization -- or CRO -- to advance the development of its ophthalmology franchise.




NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company's discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 




Sipp Industries Forms Distribution Partnership with Wanderport Corporation to Supply Premium Bulk Hemp Seed and Oil

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - Sipp Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in technology, manufacturing, and distribution of commercial and consumer products, is pleased to announce that upon exploration of their complementary synergies, a partnership was established to supply premium bulk hemp seed and oil for Wanderport's (OTC: WDRP) growing selection of consumer hemp based products and premium CBD and hemp coffee line.




National Brain Tumor Society Launches New Brain Tumor-Specific Clinical Trial Finder

Wed, 22 Mar 2017 08:30:00 EDT

New tool will make it easier for brain tumor patients to find up-to-date information on clinical trials, enabling patients to better engage with medical research and make more informed decisions about their own treatment options in the era of precision medicine




Marijuana Company of America Continues National Expansion with Production Permit in Adelanto, California

Wed, 22 Mar 2017 08:30:00 EDT

BONSALL, CA--(Marketwired - Mar 22, 2017) - MARIJUANA COMPANY OF AMERICA ("MCOA" or the "Company") (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution company, is pleased to announce that it has completed due diligence and entered into a binding joint venture agreement with GateC Research, Inc. ("GCR") for the purpose of engaging in the cultivation of legal marijuana in Adelanto, California.




MJTV Develops Two More Essential Oil Alchemys To Add On To The VOLUPTAS Project LUNA Line

Wed, 22 Mar 2017 08:00:00 EDT

WHIPPANY, NJ--(Marketwired - Mar 22, 2017) - Michael James Enterprises, Inc. (OTCQB: MJTV), is pleased to report that the company has developed two more essential oil alchemy products and is in the final test marketing for both products. This will bring MJTV essential oil product line to 3 with an additional two more essential oil mixtures to come in the near future bringing the total to 5.




Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results

Wed, 22 Mar 2017 08:00:00 EDT

LEXINGTON, MA--(Marketwired - Mar 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the year ended December 31, 2016 on Thursday, March 30, 2017, prior to the market open.




AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors

Wed, 22 Mar 2017 08:00:00 EDT

LOUISVILLE, CO--(Marketwired - March 22, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical growth company specializing in the development of innovative drug therapies for patients with diabetes and metabolic diseases, announced today the appointment of Tae Hoon Kim and Samir R. Patel, M.D. to its Board of Directors. Mr. Kim and Dr. Patel join AntriaBio's Board as the Company prepares to conduct the first-in-human clinical study for its lead product candidate, AB101, a once-weekly basal insulin in development for patients with type 1 and type 2 diabetes.